Northside BMT Program ‘significantly’ exceeds expected survival for 12th consecutive year
For a 12th consecutive year, The Blood and Marrow Transplant (BMT) Program at Northside Hospital has been recognized as having among the very best survival outcomes in the United States for bone marrow transplants.
The data were provided by the Centers for International Blood and Marrow Transplant Research (CIBMTR) in their Final 2020 Transplant Center Survival Report, which tabulated patient survival following transplantation at 172 adult and pediatric transplant centers in the U.S.
Patients who received their first allogeneic transplant between January 1, 2016 and December 31, 2018 using unrelated or related donors and who had reported follow-up were analyzed. Each center’s survival was compared to average national survival data and then statistically designated as either superior to, matching or inferior to expectations.
The one-year survival of patients transplanted at Northside was 80.8%. Northside is the only center in Georgia to achieve outcomes statistically superior to expectations and is one of only 17 centers in the U.S. to achieve this status; it also is the only center in the U.S. to achieve superior outcomes for the last 12 consecutive annual reporting cycles.
“This unmatched result of 12 consecutive years of survival outcomes that exceed expectations on the national standardized comparison of transplant centers is an astonishing achievement for Northside Hospital and for Georgia, and is an indication that patients receive the very best transplant care here,” said Dr Asad Bashey, director of clinical research for The BMT Program at Northside Hospital.
“The BMT Program at Northside Hospital is the largest allogeneic transplant center in Georgia,” added Dr. Bashey. “However, success is not just a result of our size, but of the level of expertise of our clinical teams, our dedicated state-of-the-art facilities, and the innovative policies and procedures at our center that are focused singularly at providing the very best results possible following transplantation.”
Patient-focused care, innovative treatments and clinical research utilizing cutting-edge treatments that are not generally available are major components of The BMT Program at Northside Hospital. The BMT Program offers chimeric antigen receptor (CAR) T-cell therapy and other immunotherapy treatments, including novel clinical research trials, and recently began studying an investigational treatment that uses convalescent plasma in patients currently fighting COVID-19. Northside also has pioneered the use of outpatient management even for the most complex transplant procedures and the safe use of alternative donors when conventional donors may not be available.